Meeting Â鶹´«Ă˝ Releases on News
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Outlines Guidance for Diagnosing Pediatric and Late-Onset Multiple Sclerosis
A new review led by the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) provides guidance on how to diagnose suspected multiple sclerosis (MS) in individuals under 18 and adults 50 years and older.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 26-Sep-2024 3:05 PM EDT
Making Connections will be the focus at the ACTRIMS Forum 2025
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is excited to announce its tenth annual Forum, taking place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and the Hilton West Palm...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 1-Aug-2024 12:05 PM EDT
National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year’s Barancik Prize for Innovation in MS Research.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 30-Jan-2024 11:05 AM EST
The ninth annual ACTRIMS Forum will be held Feb. 29 - March 2 in West Palm Beach, Florida.
Breaking Barriers in MS will be the focus at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 3-Aug-2023 11:30 AM EDT
Is it MS or Something Else? Updated Guide is Published to Expedite and Uncover the Answer
An international consortium led by ACTRIMS has published detailed updated recommendations for how to distinguish suspected multiple sclerosis from other look-alike disorders. This critical guidance aims to reduce the time spent to confirm an...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 19-Jul-2023 2:30 PM EDT
ACTRIMS Forum 2023 themed MS: Going Viral
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum will be held Feb. 23-25, 2023, in San Diego, California at the Marriott Marquis San Diego Marina. Themed “MS: Going Viral,” the Forum 2023, will...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 8-Sep-2022 1:05 PM EDT
ACTRIMS Board Member Dr. Amit Bar-Or Wins Barancik Prize for Innovation in MS Research
The National MS Society announced that Amit Bar-Or, MD, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania is this year’s recipient of the Barancik...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 17-Feb-2022 4:05 PM EST
Evolution of the Neuroinflammatory Response Over the Clinical Course of MS
Benjamin M. Segal, M.D., The Ohio State University, to present keynote address at ACTRIMS Forum 2021
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Feb-2021 1:05 PM EST
The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum
Forum Announcement
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 19-Jan-2021 11:40 AM EST
Q&A with Leaders of MS Virtual 2020 Conference
ACTRIMS MS Virtual 2020 Q&A with Association Leadership
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 16-Sep-2020 5:10 PM EDT
COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:50 PM EDT
First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:45 PM EDT
Evidence of an Increased Burden of Humoral Autoimmunity in the CSF and plasma of COVID-19 Patients with Comorbid Neurologic Dysfunction
Coronavirus disease 19 (COVID-19) is the most globally impactful pandemic of the past century.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:10 PM EDT
Comparison of COVID-19 outcomes between racial groups in the COViMS registry
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:05 PM EDT
COVID-19 in people with MS: A large community-based study of the UK MS Register
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:40 AM EDT
Interrupting disease modifying treatment for pregnancy in multiple sclerosis – effect on disease activity and serum neurofilament light chain
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:15 AM EDT
Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:05 AM EDT
Brain microstructural and metabolic alterations detected in vivo at the onset of the first demyelinating event
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:30 AM EDT
Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:15 AM EDT
Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:05 AM EDT
